Mountain Pacific Investment Advisers Cut Its Thermo Fisher Scientific (TMO) Position, Intercept Pharmaceuticals (ICPT) Sellers Increased By 1.86% Their Shorts

June 20, 2017 - By Michael Collier

Mountain Pacific Investment Advisers Inc decreased Thermo Fisher Scientific (TMO) stake by 3.16% reported in 2016Q4 SEC filing. Mountain Pacific Investment Advisers Inc sold 5,050 shares as Thermo Fisher Scientific (TMO)’s stock rose 8.13%. The Mountain Pacific Investment Advisers Inc holds 154,915 shares with $21.86M value, down from 159,965 last quarter. Thermo Fisher Scientific now has $69.24 billion valuation. The stock rose 0.01% or $0.02 reaching $176.27. About 75 shares traded. Thermo Fisher Scientific Inc. (NYSE:TMO) has risen 15.57% since June 20, 2016 and is uptrending. It has underperformed by 1.13% the S&P500.

Intercept Pharmaceuticals Incorporated (NASDAQ:ICPT) had an increase of 1.86% in short interest. ICPT’s SI was 5.64 million shares in June as released by FINRA. Its up 1.86% from 5.54M shares previously. With 373,100 avg volume, 15 days are for Intercept Pharmaceuticals Incorporated (NASDAQ:ICPT)’s short sellers to cover ICPT’s short positions. The SI to Intercept Pharmaceuticals Incorporated’s float is 32.06%. The stock increased 6.27% or $7.42 during the last trading session, reaching $125.82. About shares traded. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has declined 14.52% since June 20, 2016 and is downtrending. It has underperformed by 31.22% the S&P500.

Among 17 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 9 have Buy rating, 4 Sell and 4 Hold. Therefore 53% are positive. Intercept Pharmaceuticals had 28 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) earned “Overweight” rating by Barclays Capital on Wednesday, February 24. The firm earned “Outperform” rating on Wednesday, November 18 by Oppenheimer. As per Tuesday, May 31, the company rating was maintained by JMP Securities. Wedbush maintained Intercept Pharmaceuticals Inc (NASDAQ:ICPT) on Monday, August 10 with “Outperform” rating. The stock of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) earned “Underperform” rating by Morgan Stanley on Friday, April 8. Bank of America downgraded Intercept Pharmaceuticals Inc (NASDAQ:ICPT) on Wednesday, October 28 to “Underperform” rating. The firm earned “Neutral” rating on Wednesday, March 30 by Goldman Sachs. Wells Fargo initiated Intercept Pharmaceuticals Inc (NASDAQ:ICPT) on Friday, December 4 with “Market Perform” rating. Wells Fargo upgraded Intercept Pharmaceuticals Inc (NASDAQ:ICPT) on Tuesday, April 5 to “Outperform” rating. The company was maintained on Wednesday, February 24 by Wedbush.

Investors sentiment decreased to 0.99 in 2016 Q4. Its down 0.23, from 1.22 in 2016Q3. It dropped, as 37 investors sold Intercept Pharmaceuticals Inc shares while 38 reduced holdings. 19 funds opened positions while 55 raised stakes. 20.29 million shares or 0.16% more from 20.26 million shares in 2016Q3 were reported. Blackrock Gp reported 14,846 shares or 0% of all its holdings. 751,027 are owned by State Street Corp. Profund Lc reported 0.04% stake. California State Teachers Retirement Systems owns 0.01% invested in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) for 34,159 shares. Tiaa Cref Mgmt Ltd Liability Com stated it has 0.01% of its portfolio in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). Moreover, Sectoral Asset Mgmt Incorporated has 0.89% invested in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). Macquarie Grp Limited stated it has 156,611 shares or 0.03% of all its holdings. Ascend Capital Ltd Liability Corporation holds 0.23% or 42,375 shares. New York State Common Retirement Fund has 0.01% invested in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) for 35,500 shares. Utah Retirement System owns 3,100 shares. 23,736 are owned by State Board Of Administration Of Florida Retirement System. Rhumbline Advisers reported 0.01% stake. Voya Invest Mngmt Limited Liability holds 0% or 7,190 shares. Blackrock Institutional Tru Na reported 0.01% stake. Jpmorgan Chase owns 847,013 shares.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $3.15 billion. The Firm is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. It currently has negative earnings. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analysts await Thermo Fisher Scientific Inc. (NYSE:TMO) to report earnings on July, 27. They expect $2.25 EPS, up 10.84% or $0.22 from last year’s $2.03 per share. TMO’s profit will be $883.81 million for 19.59 P/E if the $2.25 EPS becomes a reality. After $2.08 actual EPS reported by Thermo Fisher Scientific Inc. for the previous quarter, Wall Street now forecasts 8.17% EPS growth.

Mountain Pacific Investment Advisers Inc increased Xylem Inc (NYSE:XYL) stake by 59,350 shares to 381,196 valued at $18.88 million in 2016Q4. It also upped Fortive Corp Com stake by 6,125 shares and now owns 209,462 shares. Commerce Bank Inc (NASDAQ:CBSH) was raised too.

Among 15 analysts covering Thermo Fisher Scientific (NYSE:TMO), 13 have Buy rating, 0 Sell and 2 Hold. Therefore 87% are positive. Thermo Fisher Scientific had 31 analyst reports since July 24, 2015 according to SRatingsIntel. Leerink Swann maintained the stock with “Buy” rating in Friday, April 28 report. The firm earned “Buy” rating on Tuesday, October 6 by Argus Research. Jefferies maintained the shares of TMO in report on Thursday, March 30 with “Hold” rating. On Friday, September 9 the stock rating was downgraded by Cleveland to “Neutral”. The firm has “Overweight” rating by JP Morgan given on Thursday, September 22. The rating was initiated by Deutsche Bank with “Buy” on Thursday, January 7. The firm has “Americas Conviction Buy List” rating by Goldman Sachs given on Tuesday, December 8. The rating was maintained by Barclays Capital on Tuesday, July 19 with “Overweight”. The firm has “Buy” rating given on Friday, July 22 by BTIG Research. The stock has “Buy” rating by Mizuho on Thursday, July 23.

Investors sentiment increased to 1.05 in 2016 Q4. Its up 0.26, from 0.79 in 2016Q3. It increased, as 52 investors sold TMO shares while 371 reduced holdings. 116 funds opened positions while 329 raised stakes. 330.70 million shares or 0.57% less from 332.58 million shares in 2016Q3 were reported. Cornerstone Cap Mngmt Limited Liability Corporation invested in 79,552 shares or 0.09% of the stock. Dodge And Cox holds 50,002 shares or 0.01% of its portfolio. State Board Of Administration Of Florida Retirement Systems reported 0.24% in Thermo Fisher Scientific Inc. (NYSE:TMO). Sunbelt Secs has invested 0% in Thermo Fisher Scientific Inc. (NYSE:TMO). California State Teachers Retirement has invested 0.24% in Thermo Fisher Scientific Inc. (NYSE:TMO). Mitsubishi Ufj & owns 849,444 shares for 0.25% of their portfolio. New South Mgmt accumulated 925,230 shares. Gw Henssler And Assoc Ltd accumulated 52,119 shares or 0.81% of the stock. Moreover, Highlander Cap Mgmt Ltd Liability Corporation has 0.03% invested in Thermo Fisher Scientific Inc. (NYSE:TMO) for 230 shares. Edgestream Prtn LP accumulated 1,700 shares. Burney Commerce has invested 0.02% in Thermo Fisher Scientific Inc. (NYSE:TMO). Great Lakes Advsrs Ltd reported 13,143 shares stake. Haverford accumulated 0.03% or 7,934 shares. Catalyst Advisors Limited, New York-based fund reported 640 shares. Exxonmobil Investment Mgmt Tx owns 0.29% invested in Thermo Fisher Scientific Inc. (NYSE:TMO) for 91,435 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: